Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may spot bone damage in multiple myeloma

NCT ID NCT02800954

Completed Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether a substance called M-CSF in the blood can help identify bone lesions in people with multiple myeloma. Researchers compared M-CSF levels in 111 participants: those with multiple myeloma, those with a pre-cancer condition called MGUS, and healthy controls. The goal was to see if M-CSF could serve as a new marker for bone damage, which is a common complication of myeloma.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If M-CSF levels prove useful, it could lead to a simple blood test to detect bone damage in multiple myeloma patients earlier.
What could go wrong
This is a small, completed observational study, not a treatment trial. The marker may not be reliable enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

monoclonal gammopathy of uncertain significance plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

  • CH Beauvais

    Beauvais, 60021, France

  • CHU Amiens

    Amiens, 80054, France

  • Ch Saint Quentin

    Saint-Quentin, 02321, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.